VEEDA CR, India’s fastest growing Clinical Research Organisation (CRO), has recently received approvals from the USFDA (US Food and Drug Association), WHO (World Health Organization) and ANVISA (Brazilian Regulatory Authority).

Binoy Gardi Group Managing Director and founder - Veeda CR said, “These regulatory approvals have merely verified and validated the high quality of work we do at Veeda.”

Apurva Shah Group Managing Director and founder - Veeda added “Quality is the corner stone of Veeda. From day one we ensured that not only are our facilities of the highest standard but so is the caliber of our people. This is why we continue to get work from 9 of the top 15 Global Pharmaceutical companies.”

Veeda has received approval for 6 studies from the USFDA which is one of the most credible regulatory authorities of the world. Getting as many as 6 Bioequivalence study approvals from USFDA without any 483’s has really enhanced Veeda’s reputation in the industry. Simultaneously, Veeda has also been successful in getting a nod from WHO for one of its studies. ANVISA (Brazilian Regulatory Body) has re-qualified Veeda’s Bioequivalence centre for the second consecutive year, which enables Veeda to continue conducting studies for drugs to be marketed in Brazil. Given Veeda’s track record in quality, they have passed these audits without any study related findings.

The Veeda CR service blends 20 years of phase I expertise in UK and Germany with the substantial benefits, both intellectual and economic, of the Indian sub Continent. With the acquisition of DICE, a highly specialised data management CRO in Brussels, Veeda CR is well placed to deliver cost effective, timely research solutions to the pharmaceutical and biotechnology industries worldwide.

Veeda CR is capable of handling all types of phase I and BA/BE studies-from technically complex trials to the more routine PK studies. We have a dedicated clinical pathology, bioanalysis, biomarker and immunogenicity laboratory which is GLP accredited. We have access to populations of patients, both treated and treatment-naïve, as well as diabetics, hypertensive and asthmatic patients and also have unrivalled access to subjects with various cancers, renal impairment and cardiovascular conditions.